Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according to toxicity prognostic factors.
Saigi
Eugeni
E
Corporació Sanitaria Parc Tauli, Sabadell, Spain. esaigi@cspt.es
Salut
Antonieta
A
Campos
Juan Manuel
JM
Losa
Ferran
F
Manzano
Hermini
H
Batiste-Alentorn
Eduard
E
Acusa
Angels
A
Vélez de Mendizabal
Edelmira
E
Guasch
Inmaculada
I
Antón
Isabel
I
D000328:Adult; D000368:Aged; D002166:Camptothecin / Q000008:administration & dosage* / Q000009:adverse effects* / Q000031:analogs & derivatives*; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D016001:Confidence Intervals; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000502:physiology; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015996:Survival Rate
D000077146:Irinotecan; D005472:Fluorouracil; D002166:Camptothecin